Differentiation of focal nodular hyperplasia and hepatocellular adenoma using qualitative and quantitative imaging features and classification and regression tree analysis.
Classification and regression tree analysis (CART)
Focal nodular hyperplasia (FNH)
Gadoxetate disodium-enhanced hepatobiliary phase
Gadoxetic acid
Hepatocellular adenoma (HCA)
Magnetic resonance imaging (MRI)
Journal
Abdominal radiology (New York)
ISSN: 2366-0058
Titre abrégé: Abdom Radiol (NY)
Pays: United States
ID NLM: 101674571
Informations de publication
Date de publication:
03 2023
03 2023
Historique:
received:
21
09
2022
accepted:
26
11
2022
revised:
25
11
2022
pubmed:
18
12
2022
medline:
25
2
2023
entrez:
17
12
2022
Statut:
ppublish
Résumé
To assess qualitative and quantitative analysis of gadoxetate disodium-enhanced hepatobiliary phase MR imaging (MRI) and assess the performance of classification and regression tree analysis for the differentiation of focal nodular hyperplasia (FNH) and hepatocellular adenoma (HCA). This retrospective study was approved by our local ethics committee. One hundred seventy patients suspected of having FNH or HCA underwent gadoxetate disodium-enhanced MRI. The reference standard was either pathology or follow-up imaging. Two readers reviewed images to identify qualitative imaging features and measure signal intensity on unenhanced, dynamic, and hepatobiliary phase images. For quantitative analysis, contrast enhancement ratio (CER), lesion-to-liver contrast (LLC), signal intensity ratio (SIR), and relative signal enhancement ratio (RSER) were calculated. A classification and regression tree (CART) analysis was developed. Eighty-five patients met the inclusion criteria, with a total of 97 FNHs and 43 HCAs. For qualitative analysis, the T1 signal intensity on the hepatobiliary phase provided the highest overall classification performance (91.9% sensitivity, 90.1% specificity, and 90.9% accuracy). For quantitative analysis, RSER in the hepatobiliary phase with a threshold of 0.723 provided the highest classification performance (92.6% sensitivity and 89.4% specificity) to differentiate FNHs from HCAs. A CART model based on five qualitative imaging features provided an accuracy of 94.4% (95% confidence interval 90.0-98.9%). Gadoxetate disodium-enhanced hepatobiliary phase provides high diagnostic performance as demonstrated in quantitative and qualitative analysis in differentiation of FNH and HCA, supported by a CART decision model.
Identifiants
pubmed: 36528729
doi: 10.1007/s00261-022-03766-0
pii: 10.1007/s00261-022-03766-0
doi:
Substances chimiques
gadolinium ethoxybenzyl DTPA
0
Contrast Media
0
Gadolinium DTPA
K2I13DR72L
Amines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
874-885Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Marrero JA, Ahn J, Rajender Reddy K. ACG clinical guideline: the diagnosis and management of focal liver lesions. Am J Gastroenterol 2014;109(9):1328-1347; quiz 1348. https://doi.org/10.1038/ajg.2014.213
doi: 10.1038/ajg.2014.213
pubmed: 25135008
Vilgrain V, Uzan F, Brancatelli G, Federle MP, Zappa M, Menu Y. Prevalence of Hepatic Hemangioma in Patients with Focal Nodular Hyperplasia: MR Imaging Analysis. Radiology 2003;229(1):75-79. https://doi.org/10.1148/radiol.2291021284
doi: 10.1148/radiol.2291021284
pubmed: 12944594
Maillette de Buy Wenniger L, Terpstra V, Beuers U. Focal Nodular Hyperplasia and Hepatic Adenoma: Epidemiology and Pathology. Digestive Surgery 2010;27(1):24-31. https://doi.org/10.1159/000268404
doi: 10.1159/000268404
pubmed: 20357448
Grazioli L, Bondioni MP, Haradome H, Motosugi U, Tinti R, Frittoli B, Gambarini S, Donato F, Colagrande S. Hepatocellular adenoma and focal nodular hyperplasia: value of gadoxetic acid-enhanced MR imaging in differential diagnosis. Radiology 2012;262(2):520-529. https://doi.org/10.1148/radiol.11101742
doi: 10.1148/radiol.11101742
pubmed: 22282184
Bieze M, van den Esschert JW, Nio CY, Verheij J, Reitsma JB, Terpstra V, van Gulik TM, Phoa SSKS. Diagnostic Accuracy of MRI in Differentiating Hepatocellular Adenoma From Focal Nodular Hyperplasia: Prospective Study of the Additional Value of Gadoxetate Disodium. American Journal of Roentgenology 2012;199(1):26-34. https://doi.org/10.2214/ajr.11.7750
doi: 10.2214/ajr.11.7750
pubmed: 22733890
McInnes MD, Hibbert RM, Inácio JR, Schieda N. Focal Nodular Hyperplasia and Hepatocellular Adenoma: Accuracy of Gadoxetic Acid-enhanced MR Imaging—A Systematic Review. Radiology 2015;277(2):413-423. https://doi.org/10.1148/radiol.2015142986
doi: 10.1148/radiol.2015142986
pubmed: 26020440
Kuo Y-H, Wang J-H, Lu S-N, Hung C-H, Wei Y-C, Hu T-H, Chen C-H, Yen Y-H, Lee C-M, Eng H-L. Natural course of hepatic focal nodular hyperplasia: A long-term follow-up study with sonography. Journal of Clinical Ultrasound 2009;37(3):132-137. https://doi.org/10.1002/jcu.20533
doi: 10.1002/jcu.20533
pubmed: 18855931
Deneve JL, Pawlik TM, Cunningham S, Clary B, Reddy S, Scoggins CR, Martin RC, D'Angelica M, Staley CA, Choti MA, Jarnagin WR, Schulick RD, Kooby DA. Liver cell adenoma: a multicenter analysis of risk factors for rupture and malignancy. Ann Surg Oncol 2009;16(3):640-648. https://doi.org/10.1245/s10434-008-0275-6
doi: 10.1245/s10434-008-0275-6
pubmed: 19130136
Farges O, Dokmak S. Malignant transformation of liver adenoma: an analysis of the literature. Dig Surg 2010;27(1):32-38. https://doi.org/10.1159/000268405
doi: 10.1159/000268405
pubmed: 20357449
Grazioli L, Bondioni MP, Haradome H, Motosugi U, Tinti R, Frittoli B, Gambarini S, Donato F, Colagrande S. Hepatocellular Adenoma and Focal Nodular Hyperplasia: Value of Gadoxetic Acid–enhanced MR Imaging in Differential Diagnosis. Radiology 2012;262(2):520-529. https://doi.org/10.1148/radiol.11101742
doi: 10.1148/radiol.11101742
pubmed: 22282184
Auer TA, Walter-Rittel T, Geisel D, Schöning W, Schmelzle M, Müller T, Sinn B, Denecke T, Hamm B, Fehrenbach U. HBP-enhancing hepatocellular adenomas and how to discriminate them from FNH in Gd-EOB MRI. BMC Med Imaging 2021;21(1):28. https://doi.org/10.1186/s12880-021-00552-0
doi: 10.1186/s12880-021-00552-0
pubmed: 33588783
pmcid: 7885421
Aalten SMv, Thomeer MGJ, Terkivatan T, Dwarkasing RS, Verheij J, Man RAd, IJzermans JNM. Hepatocellular Adenomas: Correlation of MR Imaging Findings with Pathologic Subtype Classification. Radiology 2011;261(1):172-181. https://doi.org/10.1148/radiol.11110023
doi: 10.1148/radiol.11110023
pubmed: 21875850
Tse JR, Naini BV, Lu DSK, Raman SS. Qualitative and Quantitative Gadoxetic Acid–enhanced MR Imaging Helps Subtype Hepatocellular Adenomas. Radiology 2016;279(1):118-127. https://doi.org/10.1148/radiol.2015142449
doi: 10.1148/radiol.2015142449
pubmed: 26505921
Landis JR, Koch GG. An application of hierarchical kappa-type statistics in the assessment of majority agreement among multiple observers. Biometrics 1977;33(2):363-374.
doi: 10.2307/2529786
pubmed: 884196
Breiman L, Friedman JH, Olshen RA, Stone CJ. Classification And Regression Trees. (New York, Routledge, 1984).
Ngu S, Lebron-Zapata L, Pomeranz C, Katz S, Gerst S, Zheng J, Moskowitz C, Do RK. Inter-observer agreement on the assessment of relative liver lesion signal intensity on hepatobiliary phase imaging with gadoxetate (Gd-EOB-DTPA). Abdom Radiol (NY) 2016;41(1):50-55. https://doi.org/10.1007/s00261-015-0609-3
doi: 10.1007/s00261-015-0609-3
pubmed: 26830611
Ronot M, Bahrami S, Calderaro J, Valla DC, Bedossa P, Belghiti J, Vilgrain V, Paradis V. Hepatocellular adenomas: accuracy of magnetic resonance imaging and liver biopsy in subtype classification. Hepatology 2011;53(4):1182-1191. https://doi.org/10.1002/hep.24147
doi: 10.1002/hep.24147
pubmed: 21480324
Grieser C, Steffen IG, Kramme IB, Blaker H, Kilic E, Perez Fernandez CM, Seehofer D, Schott E, Hamm B, Denecke T. Gadoxetic acid enhanced MRI for differentiation of FNH and HCA: a single centre experience. Eur Radiol 2014;24(6):1339-1348. https://doi.org/10.1007/s00330-014-3144-7
doi: 10.1007/s00330-014-3144-7
pubmed: 24658870
Grazioli L, Federle MP, Brancatelli G, Ichikawa T, Olivetti L, Blachar A. Hepatic adenomas: imaging and pathologic findings. Radiographics 2001;21(4):877-892; discussion 892-874. https://doi.org/10.1148/radiographics.21.4.g01jl04877
doi: 10.1148/radiographics.21.4.g01jl04877
pubmed: 11452062
Suh CH, Kim KW, Kim GY, Shin YM, Kim PN, Park SH. The diagnostic value of Gd-EOB-DTPA-MRI for the diagnosis of focal nodular hyperplasia: a systematic review and meta-analysis. Eur Radiol 2015;25(4):950-960. https://doi.org/10.1007/s00330-014-3499-9
doi: 10.1007/s00330-014-3499-9
pubmed: 25537979
Vander Borght S, Libbrecht L, Blokzijl H, Faber KN, Moshage H, Aerts R, Van Steenbergen W, Jansen PL, Desmet VJ, Roskams TA. Diagnostic and pathogenetic implications of the expression of hepatic transporters in focal lesions occurring in normal liver. J Pathol 2005;207(4):471-482. https://doi.org/10.1002/path.1852
doi: 10.1002/path.1852
pubmed: 16161006
Kitao A, Zen Y, Matsui O, Gabata T, Kobayashi S, Koda W, Kozaka K, Yoneda N, Yamashita T, Kaneko S, Nakanuma Y. Hepatocellular carcinoma: signal intensity at gadoxetic acid-enhanced MR Imaging—correlation with molecular transporters and histopathologic features. Radiology 2010;256(3):817-826. https://doi.org/10.1148/radiol.10092214
doi: 10.1148/radiol.10092214
pubmed: 20663969
van Kessel CS, de Boer E, ten Kate FJ, Brosens LA, Veldhuis WB, van Leeuwen MS. Focal nodular hyperplasia: hepatobiliary enhancement patterns on gadoxetic-acid contrast-enhanced MRI. Abdom Imaging 2013;38(3):490-501. https://doi.org/10.1007/s00261-012-9916-0
doi: 10.1007/s00261-012-9916-0
pubmed: 22729462
Haimerl M, Wächtler M, Zeman F, Verloh N, Platzek I, Schreyer AG, Stroszczynski C, Wiggermann P. Quantitative evaluation of enhancement patterns in focal solid liver lesions with Gd-EOB-DTPA-enhanced MRI. PLoS ONE 2014;9(6):e100315. https://doi.org/10.1371/journal.pone.0100315
doi: 10.1371/journal.pone.0100315
pubmed: 24950259
pmcid: 4065046